Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

TTP Labtech Supports Dart NeuroScience in the Study of Memory Disorders

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
TTP Labtech’s comPOUND® & comPILER® deliver scalable, secure compound storage and tube-to-plate processing.

TTP Labtech has signed an agreement with Dart NeuroScience, LLC (DNS), a specialized pharmaceutical company, to supply its modular compound storage and retrieval systems, comPOUND® and comPILER®.

The platform will enable the safe, long-term storage of the newly formed and rapidly expanding DNS small molecule compound libraries, supporting the company’s quest to discover innovative drugs and targeted therapies for life-long cognitive vitality and the treatment of memory disorders.

Through strong investment in its internal and external programs, DNS is driving new scientific discovery with some of the leading experts in this field.

Its unique approach originated from scientific findings at the Cold Spring Harbor Laboratory that identified the genes controlling fruit fly memory.

By extending the functional links of these genes to the memory of mammals, DNS has been able to apply new and advanced methodologies to identify small molecular drugs from mammalian targets.

The group is screening newly discovered gene targets involved with memory formation against small molecule compounds in order to identify those that enhance or inhibit their biochemical activity.

This is allowing DNS to fill its pipeline with exciting drug candidates for new targeted therapies and memory enhancers.

By utilizing its integrated teams of structural biologists, medicinal chemists, production and purification specialists, the organization aims to apply its target-based molecule design to create and store up to 100,000 compounds a year.

“We are delighted to announce TTP Labtech as the chosen supplier of our compound management solution. We are investing heavily in our IP portfolio and developing our own proprietary compounds in-house. As such, identifying a secure solution that will ensure compound integrity and guarantee the protection of this investment has been paramount,” commented Jose Quiroz, Manager of Laboratory Systems at Dart NeuroScience.

With a small footprint, fast automated operation and a flexible, modular design, comPOUND will prove a sturdy investment for the DNS team. “We know that TTP Labtech’s comPOUND-comPILER platform will provide the exceptional long-term storage and tube-to-plate processing capabilities that we require,” Quiroz said.

Scalability and future proofing was also a key factor for the group at DNS. “We are starting with three comPOUNDs and one comPILER system, but with the scope to integrate up to ten comPOUND stores simultaneously with our comPILER platform, we can sensibly amortize our investment. This is something that is not possible with a big integrated store requiring a significant capital outlay. Instead, we can effectively grow our library and our storage facilities in parallel - this is very appealing to us.”

James Craven, Product Manager for sample storage at TTP Labtech, described the new agreement as “collaborative” and a great example of the unique approach that the company brings to its sales process.

“We’ve worked closely with the screening and compound management teams at DNS for a number of years, supplying other products such as our mosquito and acumen, and were keen to help them find a future-proofed compound management system,” he said. “By working very closely alongside the DNS team, we could propose a comPOUND-comPILER set-up coupled with our pneumatic tube transport system, lab2lab, with everything working seamlessly together to meet their unique requirements and objectives.”

Craven continued: “We have customers with comPOUNDs that have been in place for over ten years. The plug-and-play storage units have been relocated across facilities and reinstalled on new continents as the global screening needs of the company have evolved. This makes for a sensible investment, and we tend to find that our systems are never left redundant. Our robust technology offers innovative operation and long term sample viability, making comPOUND a smart long-term investment.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

David Newble Joins TTP Labtech as New Managing Director
Recent appointment promises to drive innovation strategy and further strengthen R&D pipeline
Thursday, June 18, 2015
TTP Labtech and Almac Group’s Form Strategic Alliance
Alliance consolidates fluorescence lifetime technology to form a one-stop shop for compound screening.
Thursday, February 05, 2015
Innovative Technology Enables First Crystal Structure of mGlu5 Transmembrane Domain to be Determined
Several novel drug candidates have been identified to help treat specific neuropsychiatric disorders.
Saturday, July 19, 2014
TTP Labtech Revenues up 43%
The company has reported an impressive 43% increase in revenues and an associated increase in profits over 2013.
Monday, June 23, 2014
TTP Labtech Acquires Assets from AssayMetrics
Significant improvements in assay reagents and availability of HTS-compatible readers has propelled fluorescence lifetime technology to the vanguard of cost-effective screening technologies.
Thursday, January 09, 2014
Major Protein Structure Discovery Achieved Using TTP Labtech’s Mosquito LCP
Researchers have successfully reported the structure of a Class B G-Protein Coupled Receptor (GPCR) using lipidic cubic phase (LCP) protein crystallisation.
Friday, July 26, 2013
TTP Labtech Announces On-Going Growth
An investment of £3.8M in global R&D sees product sales grow over 20%.
Thursday, July 11, 2013
TTP Labtech Announces Company Growth
New product offering demonstrates strong commitment to product development.
Friday, May 11, 2012
Driving the Science of the Future
TTP LabTech announce that they are founding sponsors of the inaugural European Lab Automation (ELA) conference and exhibition, to be held at the Conference Centre Hamburg (CCH), Hamburg, Germany, from the 30th June-1st July.
Friday, May 20, 2011
Increased Demand Drives Queensland Compound Library Expansion
QCL capacity is increased by the acquisition of a fourth additional comPOUND® storage module.
Thursday, June 10, 2010
Improve your screening know-how with TTP LabTech at Screening Europe 2010
This year at Screening Europe 2010, TTP LabTech will be sharing its in-house expertise and technical advice with exhibition delegates in order to further improve current high content screening techniques and workflows.
Thursday, January 28, 2010
TTP LabTech Delivers Automated Chemistry System for Salt and Polymorph Screening to AstraZeneca
The three year laboratory automation project involved the design and build of a fully automated system for salt and polymorph screening of novel compounds.
Wednesday, January 28, 2009
TTP LabTech's European Roadshow
The roadshow offers the opportunity to try out the latest in low-volume liquid handling and high content screening systems, as well as learning more about compound management, instrumentation development and custom automation.
Thursday, September 13, 2007
TTP LabTech Announce US Expansion to Meet Growing Customer Demand
TTP LabTech further expands its US facilities with the recruitment of sales and customer service personnel for its East Coast office in Cambridge, MA.
Monday, July 30, 2007
TTP Extends Global Reach
After building up a strong base of customers in the USA and Europe over the past three years, TTP LabTech have now appointed distributors for Japan, India and Australia/New Zealand.
Wednesday, April 04, 2007
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos